PAREXEL is Acquired by Pamplona Capital Management

Published on: 

Applied Clinical Trials

PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.

Read the full release here.